NCT04502082View on ClinicalTrials.gov

Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ARYA-1)

PHASE1TerminatedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

April 14, 2021

Primary Completion Date

August 30, 2024

Study Completion Date

August 30, 2024

Conditions
Hepatocellular CarcinomaLiver CancerLiver NeoplasmMetastatic Liver Cancer
Interventions
BIOLOGICAL

ET140203 autologous T cell product

Autologous T cells transduced with lentivirus encoding an ET140203 expression construct

Trial Locations (2)

66205

Kansas University Medical Center, Westwood

91010

City of Hope Medical Center, Duarte

Sponsors
All Listed Sponsors
lead

Eureka Therapeutics Inc.

INDUSTRY

NCT04502082 - Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ARYA-1) | Biotech Hunter | Biotech Hunter